|Bid||19.00 x 1100|
|Ask||27.98 x 1200|
|Day's Range||19.07 - 20.00|
|52 Week Range||19.00 - 37.70|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 23, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.83|
Dr. Douglas Blayney from Stanford University to Join to Discuss Recently Announced Clinical Data NEW YORK, Oct. 19, 2018 -- BeyondSpring Inc. (NASDAQ:BYSI), a global,.
Non-small cell lung cancer (NSCLC) patients received docetaxel chemotherapy plus Plinabulin (in doses up to 20 mg/m2) versus docetaxel alone in BeyondSpring’s Phase 2 Study 105. The beneficial effect of Plinabulin on docetaxel-induced CIN was measured at doses of 0 (n=14), 5 (n=14), 10 (n=13) or 20 (n=14) mg/m2 in NSCLC patients.
If you want to know who really controls BeyondSpring Inc (NASDAQ:BYSI), then you’ll have to look at the makeup of its share registry. Insiders often own a large chunk of Read More...
BeyondSpring Inc. (BYSI) (BeyondSpring or the Company) today announced the opening of an investigator-initiated Phase 1 clinical trial with a triple combination therapy, consisting of BeyondSpring’s lead asset, Plinabulin, and Bristol-Myers Squibb's Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of small-cell lung cancer (SCLC). The trial, conducted through the Big Ten Cancer Research Consortium (Big Ten CRC), is currently enrolling subjects at Rutgers Cancer Institute of New Jersey. Jyoti Malhotra, MD, MPH, medical oncologist at Rutgers Cancer Institute, is the trial’s sponsor-investigator.
NEW YORK, Oct. 03, 2018 -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies,.
New data from the Company’s Phase 2 portion of the Phase 2/3 trial in Study 105 of Plinabulin was presented by Dr. Douglas Blayney, global Principal Investigator for BeyondSpring’s chemotherapy-induced neutropenia (CIN) development program and Professor of Medicine at Stanford University Medical Center.
BeyondSpring Inc. (BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the Company a new patent—U.S. 10076518—for certain methods of treating brain cancer with administration of BeyondSpring’s lead asset, Plinabulin, a marine-derived small-molecule. The patent covers administering Plinabulin for treatment methods by which the brain tumor is metastatic, anaplastic astrocytoma, glioblastoma multiforme, oligodendroglioma, ependymomas or a combination thereof, with patent protection until 2036. Plinabulin already has 69 patents granted in 34 countries, covering composition of matter and usage, among which 13 patents granted in the U.S. The composition of matter patent for Plinabulin is valid through 2025, with potential to extend five years to 2030.
Danforth Advisors, LLC, specialists in accounting, finance support and strategy for life science and healthcare companies, today announced additional regional leadership and support with the appointment of Robert Dickey IV as Managing Director, Mid Atlantic Region. An experienced life science executive and former investment banker, Mr. Dickey will direct the firm’s strategy and service to clients in the region’s fast-growing life science clusters. “Danforth has assembled a first-rate team with deep expertise in accounting, finance strategy and operations for life science companies, allowing both start-ups and growth-stage clients to benefit from the highest level of talent in a flexible and capital-efficient way,” said Mr. Dickey.
Data Provide Further Support for Plinabulin’ s Superior Product Profile. Clinical Data Will be Presented at 2018 IASLC 19th World Conference on Lung Cancer. NEW YORK, Sept. 06, 2018-- BeyondSpring Inc., ...
NEW YORK, Sept. 04, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that Edward Liu, Chief Financial ...
NEW YORK, Aug. 15, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present ...
Mr. Daly will be responsible for global commercial operations at BeyondSpring, as well as business development, strategic partnering and alliance management. Mr. Daly has more than 25 years of experience heading business and commercial operations for leading pharmaceutical and biotech companies, including as Executive Vice President at Takeda Pharmaceuticals U.S., where he led commercial initiatives supporting expansion into oncology, and as President of AstraZeneca’s U.S. Diabetes subsidiary.
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want access to our free research report on Seattle Genetics, Inc. (NASDAQ: SGEN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SGEN as the Company's latest news hit the wire. On July 12, 2018, the Company announced the dosing of the first patient in the Phase-2 innovaTV 207 clinical trial evaluating the activity, safety, and tolerability of tisotumab vedotin as a monotherapy in selected solid tumors with high Tissue Factor expression. Active-Investors.com is currently working on the research report for BeyondSpring Inc. (NASDAQ: BYSI), which also belongs to the Healthcare sector as the Company Seattle Genetics.
New York-based BeyondSpring develops oncology products with Plinabulin, a small molecule that attacks tumors and can activate the Rho guanine nucleotide exchange factor GEF-H1, which could play a role in managing a variety of diseases. Research has confirmed "the roles of GEF-H1 in epithelial barrier permeability, cell motility and polarization, dendritic spine morphology, antigen presentation, leukemic cell differentiation, cell cycle regulation, and cancer," according to the National Health Institutes' NCBI. "GEF-H1 might also contribute to pathophysiological signaling involved in leukemias, and in cancers associated with mutated p53 tumor suppressor gene, epithelial and endothelial cell dysfunction, infectious disease, and cardiac hypertrophy.